Adicet Bio, Inc.
NCM: ACETLive Quote
About Adicet Bio, Inc.
Healthcare
Biotechnology
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
📊 Fundamental Analysis
Adicet Bio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -67.6%, which indicates that capital utilization is currently under pressure.
At a current price of $6.76, ACET currently trades near the bottom of its 52-week range (7%), indicating potential value or weakness (Range: $6.01 - $17.44).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$68.34M
Trailing P/E
--
Forward P/E
-2.01
Beta (5Y)
1.58
52W High
$17.44
52W Low
$6.01
Avg Volume
148K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App